In order to treat neurofibromatosis 2 (NF2), a rare genetic disorder that results in numerous brain tumors along nerves, researchers are starting a ground-breaking experiment with HIV medications.
About 1 in 25,000 to 40,000 people are affected by these non-cancerous growths, which cause symptoms like hearing loss, balance problems, and persistent headaches.
A new study lead by Professor Oliver Hanemann from the University of Plymouth\’s Brain Tumour Research Centre of Excellence seeks to modify the current treatment options for NF2, which are restricted to surgery.
Twelve patients will be involved in the experiment, which is designed to evaluate two medications known to have the potential to decrease tumors: lopinavir and ritonavir.
Patients will follow a 30-day regimen while biopsies and blood tests are used by researchers to track the tumors\’ response both before and after therapy. NF2-related tumor patient Jayne Sweeney, 57, who has had numerous surgeries and chemotherapy treatments, expressed hope for the experiment.
She stated the profound impact of hearing loss caused by NF2, stressing the urgent need for more effective and less invasive treatment options.
The study builds upon promising lab findings suggesting these HIV drugs could also benefit other types of brain tumors, potentially offering a ray of hope for patients facing limited therapeutic options.
